Letters

Developed countries could pay for hepatitis B vaccination in developing countries

BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7142.1457 (Published 09 May 1998) Cite this as: BMJ 1998;316:1457
  1. N J Gay, Principal scientist,
  2. W J Edmunds, Research fellow
  1. Immunisation Division, Public Health Laboratory Service Communicable Disease Surveillance Centre, London NW9 5EQ
  2. Department of Biological Sciences, University of Warwick, Coventry CV4 7AL

    EDITOR—The debate about the most cost effective policy for vaccination against hepatitis B in the United Kingdom has centred on the relative merits of selective and universal vaccination. 1 2 A more imaginative approach is worth consideration.

    The current incidence of acute hepatitis B in the United Kingdom suggests that the lifetime risk of acquiring infection is 0.4% (excepting perinatal transmission, which is controllable by well implemented antenatal screening) (Public Health Laboratory Service, unpublished paper). If 6% of infected people are assumed to develop chronic carriage, …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe